Bone Health
Bisphosphonate and oestrogen-based tablets for osteoporosis, bone loss and fracture risk make up this small range of four medicines, including Fosamax, Evista, Actonel and Estrace.
Key points
- Bisphosphonates slow the rate at which bone is broken down and are widely used in osteoporosis.
- Bone-density testing and fracture-risk assessment help set the context for osteoporosis treatment.
- Non-bisphosphonate options are also part of osteoporosis care, including oestrogen-based Estrace, listed here for postmenopausal osteoporosis.
Fosamax, Evista and other medicines in this range
Alendronic acid is the ingredient in Fosamax, listed for osteoporosis and Paget’s disease of bone. Actonel contains risedronate, listed for the same two conditions. Raloxifene, the ingredient in Evista, is listed for postmenopausal osteoporosis and breast cancer. Estradiol in Estrace is also listed for postmenopausal osteoporosis, alongside menopausal vasomotor symptoms and atrophic vaginitis.



